Topical fluorouracil after surgery for ocular surface squamous neoplasia in Kenya: a randomised, double-blind, placebo-controlled trial Dr Stephen Gichuhi, MMed, Ephantus Macharia, HND, Joy Kabiru, MMed, Alain M'bongo Zindamoyen, MMed, Hilary Rono, MMed, Ernest Ollando, MMed, Joseph Wachira, MMed, Rhoda Munene, MMed, John Maina, CICT, Timothy Onyuma, MMed, Mandeep S Sagoo, FRCOphth, Prof Helen A Weiss, PhD, Matthew J Burton, PhD The Lancet Global Health Volume 4, Issue 6, Pages e378-e385 (June 2016) DOI: 10.1016/S2214-109X(16)30052-3 Copyright © 2016 Gichuhi et al. Open Access article distributed under the terms of CC BY Terms and Conditions
Figure 1 Ocular surface squamous neoplasia Moderately differentiated conjunctival squamous cell carcinoma, (A) moderate size, (B) large lesion involving the cornea, limbus, and extending to the fornix. Fornix involvement is often associated with orbital spread. The Lancet Global Health 2016 4, e378-e385DOI: (10.1016/S2214-109X(16)30052-3) Copyright © 2016 Gichuhi et al. Open Access article distributed under the terms of CC BY Terms and Conditions
Figure 2 Trial profile OSSN=ocular surface squamous neoplasia. The Lancet Global Health 2016 4, e378-e385DOI: (10.1016/S2214-109X(16)30052-3) Copyright © 2016 Gichuhi et al. Open Access article distributed under the terms of CC BY Terms and Conditions
Figure 3 Kaplan-Meier analysis of time to recurrence The Lancet Global Health 2016 4, e378-e385DOI: (10.1016/S2214-109X(16)30052-3) Copyright © 2016 Gichuhi et al. Open Access article distributed under the terms of CC BY Terms and Conditions